These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22568355)

  • 41. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fertilization and embryo development with spermatozoa obtained from testicular sperm extraction into oocytes generated from human chorionic gonadotropin-primed in vitro maturation cycles.
    Son WY; Chung JT; Henderson S; Reinblatt S; Buckett W; Chan PT; Holzer H
    Fertil Steril; 2013 Oct; 100(4):989-93. PubMed ID: 23806848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of duration and dose of gonadotrophins on IVF outcomes.
    Martin JR; Mahutte NG; Arici A; Sakkas D
    Reprod Biomed Online; 2006 Nov; 13(5):645-50. PubMed ID: 17169173
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation.
    Drakakis P; Loutradis D; Beloukas A; Sypsa V; Anastasiadou V; Kalofolias G; Arabatzi H; Kiapekou E; Stefanidis K; Paraskevis D; Makrigiannakis A; Hatzakis A; Antsaklis A
    Reprod Biol Endocrinol; 2009 Oct; 7():110. PubMed ID: 19825188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
    Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
    Koo YA; Lee B; Park HJ; Choi J; Lee E; Choi D
    Fertil Steril; 2009 Mar; 91(3):744-8. PubMed ID: 18321491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program].
    Tsagareishvili GG; Khonelidze NL; Lazarev AP
    Georgian Med News; 2005 Jun; (123):7-12. PubMed ID: 16052045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
    Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modified super-long down-regulation protocol improves fertilization and pregnancy in patients with poor ovarian responses.
    Zhang HJ; Song XR; Lü R; Xue FX
    Chin Med J (Engl); 2012 Aug; 125(16):2837-40. PubMed ID: 22932076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
    Maged AM; Nada AM; Abohamila F; Hashem AT; Mostafa WA; Elzayat AR
    Reprod Sci; 2015 Dec; 22(12):1627-31. PubMed ID: 26045549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth hormone co-treatment in IVF/ICSI cycles in poor responders.
    Ob'edkova K; Kogan I; Krikheli I; Dzhemlikhanova L; Muller V; Mekina I; Lesik E; Komarova E; Mazilina M; Niauri D; Gzgzyan A; Aylamazyan E
    Gynecol Endocrinol; 2017; 33(sup1):15-17. PubMed ID: 29264990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multivariate analysis of the association between oocyte donor characteristics, including basal follicle stimulating hormone (FSH) and age, and IVF cycle outcomes.
    Barton SE; Missmer SA; Ashby RK; Ginsburg ES
    Fertil Steril; 2010 Sep; 94(4):1292-1295. PubMed ID: 19819435
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is there a detrimental effect of higher gonadotrophin dose on clinical pregnancy rate in normo-responders undergoing ART with long protocol?
    Yilmaz N; Yilmaz S; Inal H; Gorkem U; Seckin B; Turkkani A; Gulerman C
    Arch Gynecol Obstet; 2013 May; 287(5):1039-44. PubMed ID: 23233291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles.
    Baker VL; Brown MB; Luke B; Smith GW; Ireland JJ
    Fertil Steril; 2015 Nov; 104(5):1145-52.e1-5. PubMed ID: 26297646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial.
    Lamb JD; Shen S; McCulloch C; Jalalian L; Cedars MI; Rosen MP
    Fertil Steril; 2011 Apr; 95(5):1655-60. PubMed ID: 21315341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.